Variant Gene Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer. 31589789

2020

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer. 31566309

2019

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Detection of the BRAF V600E Mutation in Colorectal Cancer by NIR Spectroscopy in Conjunction with Counter Propagation Artificial Neural Network. 31208050

2019

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE <i>BRAF</i> (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival. 30719102

2019

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Circulating 25(OH)D was also inversely associated with <i>BRAF</i> V600E-positive colorectal cancer (per 25 nmol/L increment: HR, 0.71; 95% CI, 0.50-1.01). 30842127

2019

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Previous studies have reported that rafoxanide, as an inhibitor of BRAF V600E mutant protein, inhibits the growth of colorectal cancer, multiple myeloma, and skin cancer. 31678170

2019

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer. 30963570

2019

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma. 30883505

2019

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Here, we investigate molecular responses upon single and multi-target treatments, over time, using BRAF(V600E) mutant colorectal cancer cells as a model system. 29970458

2018

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma. 30335711

2018

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions. 30463788

2018

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE In the context of colorectal cancer, we present a method for constructing a surrogate biomarker that is able to predict with high accuracy whether a sample belongs to the "BRAF-positive" group, a high-risk group comprising V600E BRAF mutants and BRAF-mutant-like tumors. 28523274

2017

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. 27354468

2017

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Alterations in <i>MEK1/2</i> occur in cancers, both in the treatment-naïve state and following targeted therapies, most notably BRAF and MEK inhibitors in <i>BRAF</i>-V600E-mutant melanoma and colorectal cancer. 28655712

2017

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE BRAF was mutated in 7.6% (484 of 6353) of colorectal cancer and 9.1% (29 of 317) of SBA samples, but V600E mutations were much less common in SBA, representing only 10.3% (3 of 29) of BRAF-mutated cases. 28617917

2017

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer. 27672042

2017

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma. 26787892

2016

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer. 27624806

2016

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Concomitant with such properties, EBI-907 exhibits potent and selective cytotoxicity against a broader range of BRAF(V600E)-dependent cell lines including certain colorectal cancer cell lines with innate resistance to Vemurafenib. 26810733

2016

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia. 25862899

2015

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating colorectal cancer harboring BRAF(V600E) mutation. 26208524

2015

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer. 26496026

2015

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE This improved classification of serrated lesions including immunohistochemical evaluation of BRAF V600E mutation may be the key to identify lesions with higher potential to progression into sessile serrated adenoma/polyp, and further to BRAF V600E-mutated colorectal cancer. 23887306

2014

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE An MAFG-containing corepressor complex induces CIMP in BRAF(V600E)-positive colorectal cancer. 25367952

2014

dbSNP: rs121913377
rs121913377
Malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE In conclusion, miR-145 might be used as a therapeutic target in the treatment of colorectal cancer patients with BRAF V600E mutation. 24248543

2014